A small early study of tiny radioactive sources placed inside glioblastoma that has come back. By November 2026 eight people had been treated and all were alive; the tumour had shrunk or disappeared on scans in the six assessed so far. There is no comparison group, follow-up is short, and half of the responses still need a confirming scan.
REGAIN is a prospective, open-label, single-arm device study of intratumoural diffusing alpha-emitter radiotherapy (Alpha DaRT, titanium sources loaded with radium-224) for recurrent glioblastoma, registered as NCT06910306 by Alpha Tau Medical with 20 participants planned and three US sites listed. The registry gives no phase (a device feasibility study). Its primary endpoints are feasibility (successful placement of the sources) and safety (unanticipated grade 3 or higher adverse events); radiographic response by RANO criteria and overall survival to 12 months are secondary.
The Society for Neuro-Oncology 2026 abstract (Palmer and colleagues, Neuro-Oncology supplement) reports the safety analysis the FDA required after three patients, with data to May 2026: all planned sources deployed in all three, no unanticipated serious adverse event within 90 days, one grade 3 serious adverse event (a seizure with Todd's paralysis within 10 days of the implant, a 48-hour hospital stay, resolved with steroids), two complete responses on the 3-month MRI and one patient with a 30% decrease counted as stable disease.
The sponsor's release of 15 November 2026 updates this to a data cutoff of 11 November 2026, from the poster shown at the meeting: eight patients treated, all at Ohio State, with planned sources deployed in all eight and no unanticipated serious adverse event. Six had reached MRI assessment and all six had a RANO objective response as their best response: five complete responses (three confirmed, two awaiting confirmation) and one partial response (a 58% decrease, awaiting confirmation). The other two treated patients had not yet been assessed. All eight were alive; median follow-up from enrolment in the six assessed patients was 6.9 months (range 3.1 to 11.6) and median overall survival had not been reached.
Follow-up scans showed necrosis or suspected necrosis in or around the treated area in four of the six, all without symptoms. In two of those four, new or increased enhancement next to or outside the treated area could not yet be called necrosis or progression, and the sponsor says its recurrence figures may change. One patient progressed away from the treated area about nine months after treatment.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
20 enrolled.
One grade 3 serious adverse event was reported, a seizure with temporary paralysis that resolved; safety follow-up was not complete
Source5 complete (3 confirmed, 2 awaiting confirmation) and 1 partial (awaiting confirmation); 2 treated patients not yet assessed
SourceMedian overall survival not reached; median follow-up 6.9 months (range 3.1 to 11.6) in the six assessed patients
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Feasibility: planned sources deployedprimary | Alpha DaRT | 8 | 100 % of treated patients | - | - | link |
| Safety: unanticipated serious adverse eventsprimary | Alpha DaRT | 8 | 0 patients | - | - | link |
| Best radiographic response by RANO (complete or partial) | Alpha DaRT | 6 | 100 % of assessed patients | - | - | link |
| Alive at data cutoff | Alpha DaRT | 8 | 100 % of treated patients | - | - | link |
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/